Avaii Wealth Management’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.55M Sell
28,301
-804
-3% -$32.9K 0.46% 34
2026
Q1
$967K Buy
29,105
+1,946
+7% +$58K 0.34% 40
2025
Q4
$810K Buy
27,159
+110
+0.4% +$3.59K 0.29% 46
2025
Q3
$977K Buy
27,049
+676
+3% +$22.3K 0.37% 39
2025
Q2
$949K Sell
26,373
-2,927
-10% -$109K 0.42% 31
2025
Q1
$1.16M Sell
29,300
-1,093
-4% -$36.8K 0.62% 24
2024
Q4
$915K Buy
30,393
+1,409
+5% +$40.4K 0.45% 30
2024
Q3
$678K Sell
28,984
-1,249
-4% -$27.3K 0.34% 43
2024
Q2
$538K Buy
30,233
+342
+1% +$5.46K 0.3% 59
2024
Q1
$455K Buy
29,891
+608
+2% +$9.69K 0.27% 70
2023
Q4
$500K Sell
29,283
-4,739
-14% -$55.1K 0.33% 68
2023
Q3
$284K Buy
34,022
+15,468
+83% +$216K 0.22% 101
2023
Q2
$461K Sell
18,554
-240
-1% -$6.2K 0.35% 66
2023
Q1
$283K Buy
18,794
+1,934
+11% +$29.4K 0.25% 96
2022
Q4
$199K Buy
16,860
+2,943
+21% +$21.4K 0.18% 120
2022
Q3
$82K Buy
+13,917
New +$91.3K 0.09% 108
2022
Q2
Sell
-17,554
Closed -$167K 121
2022
Q1
$167K Buy
+17,554
New +$203K 0.15% 109

Other funds holding TGTX

Avaii Wealth Management's TGTX Position: Q2 2026 in Review

Avaii Wealth Management reduced its TG Therapeutics (TGTX) stake by 2.8% in Q2 2026, selling an estimated $32.9K and leaving 28,301 shares worth $1.55M. The position accounts for 0.46% of the portfolio, ranked #34.

Avaii Wealth Management first reported a position in TGTX in Q1 2022 and has held it in 17 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Avaii Wealth Management held 28,301 shares of TG Therapeutics worth $1.55M as of Q2 2026.
  • Avaii Wealth Management sold 804 TG Therapeutics shares in Q2 2026, an estimated $32.9K.
  • TG Therapeutics made up 0.46% of Avaii Wealth Management's portfolio in Q2 2026, its #34 holding.
  • Avaii Wealth Management first reported a position in TG Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Avaii Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.